WuXi Girds For Rising Yuan, Weakening U.S. Dollar
This article was originally published in PharmAsia News
Executive Summary
WuXi PharmTech believes it is prepared, unlike some of its Chinese outsourcing competitors, for the expected appreciation of the Chinese yuan, which could affect business from U.S. firms as the dollar weakens and it becomes more expensive to outsource to China
You may also be interested in...
WuXi PharmaTech Launches Talent Flow with Acquired U.S. Firm AppTec
BEIJING - WuXi PharmaTech, one of China's leading contract research organizations, is moving rapidly to integrate operations and foster a talent flow with its recently acquired American biologics outfit AppTec Laboratory Services
WuXi PharmaTech Launches Talent Flow with Acquired U.S. Firm AppTec
BEIJING - WuXi PharmaTech, one of China's leading contract research organizations, is moving rapidly to integrate operations and foster a talent flow with its recently acquired American biologics outfit AppTec Laboratory Services
Shanghai ChemPartner CEO Michael Hui On Finding A Niche In China Amidst Increasing Foreign Competition: An Interview With PharmAsia News (Part 2 of 2)
Shanghai ChemPartner was set up in 2003 at Shanghai's Zhangjiang Hi-Tech Park, and today it is one of the leading R&D outsourcing providers in China. PharmAsia News recently visited company headquarters to meet Michael Hui, CEO of ChemPartner - as well as sister company ChemExplorer, and their holding company ShangPharma - to discuss the company's recent deal with private equity investment firm TPG, as well as handling increased competition from foreign firms moving into China.